A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer

Background Inhibition of the programmed cell death protein 1 (PD‐1) pathway has demonstrated clinical benefit in metastatic urothelial cancer (mUC); however, response rates of 15% to 26% highlight the need for more effective therapies. Bruton tyrosine kinase (BTK) inhibition may suppress myeloid‐der...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Cancer Ročník 126; číslo 20; s. 4485 - 4497
Hlavní autoři:	Zhang, Tian, Harrison, Michael R., O'Donnell, Peter H., Alva, Ajjai S., Hahn, Noah M., Appleman, Leonard J., Cetnar, Jeremy, Burke, John M., Fleming, Mark T., Milowsky, Matthew I., Mortazavi, Amir, Shore, Neal, Sonpavde, Guru P., Schmidt, Emmett V., Bitman, Bojena, Munugalavadla, Veerendra, Izumi, Raquel, Patel, Priti, Staats, Janet, Chan, Cliburn, Weinhold, Kent J., George, Daniel J.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Wiley Subscription Services, Inc 15.10.2020 John Wiley and Sons Inc
Témata:	Alanine Alanine transaminase Anemia Apoptosis Bladder cancer Bruton's tyrosine kinase Cancer CD8 antigen Cell activation Cell death Correlation analysis Immune system Immunotherapy Kinases Lymphocytes Lymphocytes T Metastases Metastasis Monoclonal antibodies Monocytes Oncology Original Patients Pembrolizumab Platinum programmed cell death receptor 1 protein kinase inhibitor Protein-tyrosine kinase Solid tumors Suppressor cells Survival Targeted cancer therapy Tumors Tyrosine Urinary tract urologic neoplasms Urothelial cancer Urothelial carcinoma protein kinase inhibitor programmed cell death receptor 1 immunotherapy urologic neoplasms
ISSN:	0008-543X, 1097-0142, 1097-0142
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!